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The value of blood cultures in community-acquired pneumonia (CAP) has been questioned. At issue is the potential
for blood cultures to change management. We prospectively studied the yield and impact of blood cultures
in patients admitted with CAP. Two hundred and nine subjects had at least two blood cultures prior to receiving
antibiotics. The severity of CAP was graded using the Pneumonia Severity Index (PSI). Twenty-nine
patients (13?9%) had a pathogen identified by blood culture. The yield of blood cultures increased with PSI
grade (I—5?3%, II—10?2%, III—10?3%, IV—16?1%, V—26?7%), as did the likelihood of blood cultures
changing antibiotic therapy (I to III 0%, IV—9?7%, V—20?0%). One hundred and seventy-nine (85?6%) patients
received a quinolone, limiting the impact of pathogens resistant to b-lactams. Four of 16 patients (25?0%) with a
culture (blood or sputum)-guided change in antibiotic therapy died, compared to five of 31 patients (16?1%) who
had an empiric change. Blood cultures are of minimal value in mild to moderate CAP, and should be limited
to patients with PSI grade IV or V CAP unless a specific risk factor for pathogens resistant to the empiric therapy
is present.
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Blood cultures have a long established role as part of the
investigation of a patient admitted for treatment of
community-acquired pneumonia (CAP). Although recently
their usefulness has been questioned (1–4), most physicians
continue to order blood cultures on all patients with CAP
severe enough to require hospitalization. This is largely due
to the possibility of a positive culture having a significant
impact on patient care.
In most major epidemiological studies of CAP, the yield
of blood cultures has ranged been between 4% and 18%
(5). As bacteremia is an independent predictor of adverse
outcome (6), it is not surprising that the yield of blood
cultures is highest in epidemiological studies of severe
community-acquired pneumonia (7–9).
The current cost conscious healthcare climate has forced
physicians to re-evaluate the cost benefit of many investiga-
tions. Identifying subgroups of patients in whom a
diagnostic test will have a high yield and a high likelihoodReceived 4 August 2000 and accepted 12 October 2000. Published
online 28 November 2000.
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cost–benefit equation, provided that there is no detrimental
effect on the outcome of patients in whom the test is
withheld.
The Pneumonia Severity Index (PSI) developed by Fine
et al. (10) is one method of classifying patients with CAP
into low risk or high risk categories based on demographic,
clinical, laboratory and radiological features at admission.
Since the mortality rate of PSI grades I-III is significantly
less than 1% (10), we hypothesized that blood cultures
would only have a significant impact on patient manage-
ment in patients in PSI grades IV and V. We tested this
hypothesis in an ongoing prospective cohort study of CAP
in a large private hospital system.
Methods
SUBJECTS
Subjects were recruited into a prospective cohort study of
CAP at Methodist Healthcare between October 1998 and
June 2000. To be included in the study patients had to be 18
years or older, have symptoms and signs consistent with a
lower respiratory tract infection and have a new radi-
ological infiltrate consistent with pneumonia as determined
by a radiologist or pulmonary/critical care physician. For
the purpose of this analysis, patients were only included if# 2000 HARCOURT PUBLISHERS LTD
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antibiotics, including oral antibiotics.
Subjects were excluded if they were non-ambulatory
nursing home patients, had received chemotherapy in the
past 30 days, had been hospitalized within the past 30 days,
had AIDS as defined by the Center for Diseases Control
criteria (11) or were receiving immunosuppressant therapy
for any reason (including corticosteroids 20mg day71 of
prednisone).
This study was approved by the Institutional Review
Board of Methodist Healthcare, Memphis, U.S.A.
DATA COLLECTION
Demographic data, the initial antibiotic treatment, culture
results, subsequent modification of treatment, complica-
tions and outcome were recorded. Clinical data sucient to
calculate both the Acute Physiological and Chronic Health
Evaluation (APACHE) II score (12) and the PSI score (10)
were also obtained.
A change in management was defined as any change in
the dose of antibiotic, or the addition or discontinuation of
one or more antibiotics. The reason for any management
change was obtained from the documentation in the patient
chart with clarification as necessary from the treating
physician.
STATISTICAL ANALYSIS
Statistical calculations were performed using the InStat
Statistical Software Package Version 3.01 (GraphPad
Software Inc., U.S.A.). Variables are expressed as mean+
standard deviation unless otherwise stated. Differences in
continuous variables were compared using a two-tailed
Student’s t-test after ensuring normal distribution. Differ-
ences in categorical variables were calculated using Fisher’s
Exact Probability Test. A P50?05 was considered
significant.TABLE 1. The yield and impact of blood cultures by PSI grade
Pneumonia S
I II
Subjects 19 59 39
Subjects with at least
one positive culture
2 (10?5%) 7 (11?9%) 4
False positive cultures 1 (5?3%) 1 (1?7%) 0
Subjects with pathogen
identified by culture
1 (5?3%) 6 (10?2%) 4
Subjects where culture
changed management
0 (0%) 0 (0%) 0Results
Two hundred and nine subjects met the criteria for review
during the study period. There were 109 female (52?2%)
and 100 male (47?8%) subjects with a mean age of 59?3
years (range 18–98). Twenty-two subjects died (10?5%).
Thirty-eight subjects (18?2%) had at least one positive
blood culture. The organism cultured in nine subjects was
considered to be a contaminant (Staphylococcus epidermidis
— six, Diptheroids—three). Twenty-nine patients (13?9%)
had a total of 31 pathogens identified from blood cultures
(Streptococcus pneumoniae—20, S. viridans—three, Haemo-
philus influenzae—one, Staphylococcus aurens—one, Enter-
obacter agglomerans—one, Eschericia coli—one,
Streptococcus group B—one, Streptococcus group D—
one, Streptococcus group G—one, Acinetobacter lwo—
one). In five patients, the same organism was isolated from
sputum (all S. pneumoniae), and in one patient with
pneumococcal bacteremia, H. influenzae was also isolated
from sputum. Of the 20 S. pneumoniae isolated; seven had
penicillin minimal inhibitory concentrations (MICs)
between 0?0625 mgml71 and 1?0mgml71 and three had
MICs for penicillin 2 mgml71; seven had MICs for
cefotaxime between 0?5mgml71 and 2?0mgml71 and one
isolate had an MIC for cefotaxime of 4mgml71; 11 isolates
were resistant to erythromycin and all isolates were fully
sensitive to levofloxacin and vancomycin.
Table 1 summarizes both the yield of blood cultures and
their impact on management by the severity of pneumonia
as classified by the PSI. The trend towards an increasing
yield of pathogens from blood cultures with increasing PSI
grade was statistically significant (P¼0?02).
Twelve of the 29 (41%) patients had a management
change based on the blood culture results. In seven (PSI
grade V—five, PSI grade IV—two) antibiotic therapy was
intensified (add vancomycin—five, add ampicillin/sulbac-
tam—one, add both vancomycin and ampicillin/sulbac-
tam—one), four of whom subsequently died. In only one
patient, who subsequently died, was a change in therapy
chosen (group D Streptococcus resistant to levofloxacin). Ineverity Index Grade
III IV V Total
62 30 209
(10?3%) 14 (22?6%) 11 (36?7%) 38 (18?2%)
(0%) 4 (6?5%) 3 (10?0%) 9 (4?3%)
(10?3%) 10 (16?1%) 8 (26?7%) 29 (13?9%)
(0%) 6 (9?7%) 6 (20?0%) 12 (5?7%)
TABLE 3. Change in antibiotic therapy and subsequent
mortality
Survived Deceased Total
Blood culture positive
Change in antibiotics 8 (66.7%) 4 (33.3%) 12
No change in antibiotics 13 (76.5%) 4 (24.5%) 17
Blood culture negative
Change in antibiotics 31 (86.1%) 5 (13.9%) 36
No change in antibiotics 135 (93.8%) 9 (6.2%) 144
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of whom survived, antibiotic therapy was decreased, either
by stopping one or more antibiotics or changing to a more
narrow spectrum antibiotic. As shown in Table 2,
levofloxacin and trovafloxacin were the most popular
agents as empiric therapy (85?6%), although many different
combinations were used.
In 36 of the 180 (20%) patients with negative or false
positive blood cultures an increase in antibiotic therapy was
made during the first 5 days after admission. Five of these
36 patients subsequently died (13?9%). In five cases, the
change was due to the results of sputum culture (Pseudo-
monas aeruginosa—three, Stenotrophomonas maltophilia—
one, Achromobacter xylosoxidans—one), none of whom
died. All other increases in antibiotic therapy were not
guided by any microbiological results. A summary of
subsequent mortality following a change in management
stratified by blood culture status is shown in Table 3. No
patient with negative cultures had a narrowing of antibiotic
therapy.
The length of hospital admission by PSI grade was
I—3?8+2?3 days, II—5?7+4?4 days, III—8?5+10?2 days,
IV—11?3+9?4 days and V—15?1+14?3 days.
Discussion
In a prospective study of patients with CAP, we have
shown that the yield of blood cultures increases signifi-
cantly with the severity of pneumonia, and that positive
cultures only impacted on the management of patients
with PSI grade IV and V pneumonia. The very clear
correlation between the severity of pneumonia, as measured
by the PSI, and the sensitivity of blood culture, as well asTABLE 2. Initial empiric antibiotic therapy
Antibiotic regimen Number of
patients
Quinolone* 126 (60?3%)
Quinolone*+cephalosporin{ 16 (7?7%)
Quinolone*+other 16 (7?7%)
Cephalosporin{+macrolide{ 12 (5?7%)
Quinolone*+macrolide{ 10 (4?8%)
Other b-lactum# 6 (2?9%)
Quinolone*+cephalosporin{+other 6 (2?9%)
Quinolone*+cephalosporin{+macrolide{ 5 (2?4%)
Cephalosporin{ 5 (2?4%)
Macrolide{ 4 (1?9%)
Other b-lactum#+other 3 (1?4%)
Penicillin 0 (0?0%)
Total 209
*Levofloxacin or trovafloxacin;
{ cefotaxime or ceftriaxone;
{ erythromycin, clarithromycin or azithromycin;
# ampicillin, ticarcillin or piperacillin.the fact that a positive blood culture only impacted on the
management of patients with PSI grade IV or V pneumo-
nia, confirmed our hypotheses. This suggests that blood
cultures do not need to be performed routinely on all cases
of CAP and can safely be limited to specific patient
subgroups.
Our overall mortality of 10?5% is consistent with other
recent studies of patients hospitalized with CAP (13–16).
The positive yield of 13?9% for blood cultures in our study
is close to the most favorable sensitivities reported (5). This
high yield is probably explained by our exclusion of
patients who did not have blood cultures taken prior to
the commencement of antibiotic therapy, since prior
antibiotic therapy substantially reduces the likelihood of a
positive culture (17,18).
The finding that pathogens identified by blood culture
were resistant to the empiric antibiotic regimen chosen in
only one case was surprising. The main reason appears to
be the choice of a quinolone as part of the initial empiric
therapy regimen in 85?6%, which negated the problem of
penicillin and cephalosporin resistant pneumococci. That
physicians chose to increase antibiotic therapy in some
cases despite culture results indicating the current antibiotic
choices to be appropriate was also interesting. As the
subsequent mortality rate in these patients demonstrates
(57%), these patients were clearly critically ill and not
responding to therapy.
Based on our data, we would recommend that blood
cultures not be ordered routinely on patients with PSI grade
I to III CAP. Some patients, particularly those with chronic
suppurative lung disease (9,19), are at greater risk of having
drug resistant or unusual pathogens. Although most of
these patients will fall into PSI grades IV or V if they
develop pneumonia, continuing to order blood cultures in
patients with mild to moderate CAP when a specific risk
factor for drug resistant or unusual pathogens is probably
justified.
The argument in favor of performing blood cultures is
both clinical and epidemiological. From a clinical perspec-
tive, proponents argue that a positive blood culture may
reveal a pathogen not being covered by the antibiotic
regimen, or that the antibiotic sensitivity of the organism
identified will allow the physician to narrow the spectrum
of antibiotic therapy. Two studies have shown that initial
inappropriate antimicrobial treatment is an independent
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death increased between five (20) and 20-fold (19).
However, in patients with CAP failing to respond to initial
antibiotic therapy, Sanyal et al. (16) found no difference in
mortality between patients in whom antibiotics were
changed empirically and in those who had a change in
therapy guided by a positive microbiological study. Our
findings are similar, with a mortality of 16?1% (5/31) in
patients with a blind change in antibiotic therapy compared
to 25?0% (4/16) in patients with a microbiologically (blood
and sputum)-guided change in therapy. Although this
appears counter intuitive, Austrian and Gold’s original
work in pneumococcal pneumonia found that antibiotics
have no demonstrable impact on outcome in the first 3 days
after commencing therapy (21). Any change in antibiotic
therapy based on culture results is also unlikely to have any
impact on outcome for several days. Allowing sucient
time for a change in therapy to have an influence on
outcome, the identification of a pathogen not covered by
the initial empiric antibiotic regimen will not have a
beneficial effect on outcome for 5–6 days after admission.
By this time, the ultimate outcome of most patients has
already been determined.
Narrowing antibiotic therapy may certainly be bene-
ficial, both as a cost-saving measure and by potentially
reducing the likelihood of antibiotic resistance. However,
we have previously shown that physicians are reluctant to
use narrow antibiotic therapy even when culture results
indicate this is appropriate (4). As the length of hospital
stay is proportional to the severity of pneumonia, the
decision to discharge a patient with mild CAP is also
frequently made before antibiotic sensitivity results are
known. This further reduces the impact of blood cultures in
these patients.
Accurate local epidemiological data on the microbiolo-
gical etiology of CAP is critical to physicians in making
decisions about initial empiric antibiotic therapy. However,
taken in isolation, blood cultures are likely to give a
skewed view of the etiology of pneumonia. Mycoplasma
pneumoniae and Chlamydia pneumoniae are not detected
by blood culture and the vast majority of Legionella
infections also remain undetected (22). As invasive pneu-
mococcal isolates are also less likely to be antibiotic
resistant than non-invasive isolates (23), antibiotic resis-
tance data based only on blood cultures will also be biased.
So although providing critical epidemiological information,
the results of blood cultures can only be evaluated in the
context of a comprehensive microbiologicl study (including
sputum culture, urinary antigen testing and serological
studies).
In summary, in the clinical setting of mild to moderate
community-acquired pneumonia, blood cultures had a low
yield and no impact on management. While the yield of
blood cultures is higher in patients with more severe
pneumonia, there was no evidence that a change in
antibiotic therapy based on a positive blood culture result
led to an improved outcome. We recommend that blood
cultures be used routinely only for patients with severe
community-acquired pneumonia (PSI grades IV and V) or
in patients with specific risk factors that predispose topathogens not typically covered by standard empiric
therapy regimes. While useful epideminologically, blood
cultures results alone are misleading unless interpreted in
the context of a comprehensive microbiological survey of
etiology.
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